1 |
Baek SM, Kwon CH, Kim JH, et al (2003). Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell death in renal proximal tubular epithelial cells. J Lab Clin Med, 142, 178-86.
DOI
|
2 |
Barr DB, Wilder LC, Caudill SP, et al (2005). Urinary Creatinine Concentrations in the U.S. Population: Implications for Urinary Biologic Monitoring Measurements. Environ Health Perspect, 113, 192-200.
|
3 |
Basu S (2008). -isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Antioxid Redox Signal, 10, 1405-34.
DOI
|
4 |
Chirinoa YI, Pedraza-Chaverri J (2009) Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. J Exper Tox Path, 61, 223-42
DOI
ScienceOn
|
5 |
Dalaveris E, Kerenidi T, Katsabeki-Katsafli A, et al (2009). VEGF, TNF- and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer. Lung Cancer, 64, 219-25.
DOI
ScienceOn
|
6 |
Davies SS, Zackert W, Luo Y, et al (2006). Quantification of dinor, dihydro metabolites of -isoprostanes in urine by liquid chromatography/tandem mass spectrometry. Anal Biochem, 348, 185-91.
DOI
|
7 |
De Castro J, Hernandez-Hernandez A, Rodriguez MC, Llanillo M, Sanchez-Yague J (2006). Comparison of changes in erythrocyte and platelet fatty acid composition and protein oxidation in advanced non-small cell lung cancer. Cancer Invest, 24, 339-45.
DOI
|
8 |
Fabbro ED, Dalal S, Bruera E (2006). Symptom Control in Palliative Care-Part II: Cachexia/Anorexia and Fatigue. J Pall Med, 9, 409-21.
DOI
|
9 |
Garde AH, Hansen AM, Kristiansen J, Knudsen LE (2004). Comparison of Uncertainties Related to Standardization of Urine Samples with Volume and Creatinine Concentration. Ann Occup Hyg, 48, 171-9.
DOI
|
10 |
Gupta A, Srivastava S, Prasad R, et al (2010). Oxidative stress in non-small cell lung cancer patients after chemotherapy: association with treatment response. Respirology, 15, 349- 56.
DOI
|
11 |
Helmersson J, Basu S (1999). -isoprostane excretion rate and diurnal variation in human urine. Prostaglandins Leukot Essent Fatty Acids, 61, 203-5.
DOI
|
12 |
Il'yasova D, Kennedy K, Spasojevic I, et al (2010). Individual responses to chemotherapy-induced oxidative stress. Breast Cancer Res Treat, 125, 583-9.
|
13 |
Janssen LJ (2001). Isoprostanes: an overview and putative roles in pulmonary pathophysiology. Am J Physiol Lung Cell Mol Physiol, 280, 1067-82.
DOI
|
14 |
Janssen LJ (2008). Isoprostanes and lung vascular pathology. Am J Respir Cell Mol Biol, 39, 383-9.
DOI
|
15 |
Kadiiska MB, Gladen BC, Baird DD, et al (2005). Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med, 38, 698-710.
DOI
|
16 |
Kannan K, Jain SK (2000). Oxidative stress and apoptosis. Pathophysiology, 7, 153-63.
DOI
ScienceOn
|
17 |
Liang Y, Wei P, Duke RW, et al (2003). Quantification of 8-isoprostaglandin- F(2alpha) and 2,3-dinor-8-iso-prostaglandin- F(2alpha) in human urine using liquid chromatographytandem mass spectrometry. Free Radic Biol Med, 34, 409-18.
DOI
|
18 |
Lieberthal W, Triaca V, Levine J (1996). Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol, 270, 700-8.
|
19 |
Montuschi P, Barnes PJ, Roberts LJ (2004). Isoprostanes: markers and mediators of oxidative stress. FASEB J, 18, 1791-800.
DOI
|
20 |
Montuschi P, Barnes PJ, Roberts LJ (2007). Insights into oxidative stress: the isoprostanes. Curr Med Chem, 14,703- 17.
DOI
|
21 |
Moore K, Roberts LJ (1998). Measurement of lipid peroxidation. Free Radic Res, 28,659-71.
DOI
ScienceOn
|
22 |
Morrow JD, Hill KE, Burk RF, et al (1990). A series of prostaglandin -like compounds are produced in vivo in humans by a non-cyclooxygenase free radical catalyzed mechanism. Proc Natl Acad Sci USA, 87, 9383-7.
DOI
ScienceOn
|
23 |
Morrow JD, Harris TM, Roberts LJ (1990). Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids. Anal Biochem, 184,1-10.Roberts LJ & Morrow JD (2000). Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med, 28, 505-13.
DOI
|
24 |
Morrow JD, Roberts LJ (1994). Mass spectrometry of prostanoids: F2-isoprostanes produced by non-cyclooxygenase free radical-catalyzed mechanism. Methods Enzymol, 233, 163-74.
DOI
|
25 |
Morrow JD, Roberts LJ (1996). The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol, 51, 1-9.
DOI
|
26 |
Salahudeen A, Poovala V, Parry W, et al (1998). Cisplatin induces N-acetyl cysteine suppressible -isoprostane production and injury in renal tubular epithelial cells. J Am Soc Nephrol, 9, 1448-55.
|
27 |
Srivastava AN, Gupta A, Srivastava S, et al (2010). Cisplatin combination chemotherapy induces oxidative stress in advance non small cell lung cancer patients. APJCP, 11, 465-71.
|
28 |
Villanueva MT (2011). Targeted therapies: Evolve and ... surrender! Nature Rev Clin Oncol, 8, 315.
|
29 |
Yan W, Byrd GD, Ogden MW (2007). Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/MS. J Lipid Res, 48, 1607-17.
DOI
|
30 |
Zhang B, Saku K (2007). Control of matrix effects in the analysis of urinary -isoprostanes using novel multidimensional solid-phase extraction and LC-MS/MS. J Lipid Res, 48, 733-44.
DOI
|
31 |
Zieba M, Nowak D, Suwalski M, et al. (2001). Enhanced lipid peroxidation in cancer tissue homogenates in non-small cell lung cancer. Monaldi Arch Chest Dis, 56, 110-4.
|